Amine oxidases and their inhibitors: What can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?

Journal of Psychiatry and Neuroscience

Volumn 32, Issue 5, 2007, Pages 313-315

  Baker, Glen B ^a,b   Sowa, Bernard ^a   Todd, Kathryn G ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Amine oxidase inhibitors; Deprenyl; Monoamine oxidase; Phenelzine; Semicarbazide sensitive amine oxidase

Indexed keywords

10 (N METHYL N PROPARGYLAMINOMETHYL)DIBENZO[B,F]OXEPIN; AMINE; AMINE OXIDASE (COPPER CONTAINING); MOCLOBEMIDE; PHENELZINE; RASAGILINE; SELEGILINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY DISORDER; DOWN REGULATION; EDITORIAL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIA; MENTAL DISEASE; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PANIC; PARKINSON DISEASE;

EID: 34848922150     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (37)

1. Gerlach M, Youdim MB, Riederer P. Pharmacology of Selegiline. Neurology 1996;47(Suppl 3):S137-S145.
2. Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 2003;110:509-15.
3. Magyar K, Szende B. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 2004;25:233-42.
4. Sowa BN, Todd KG, Tanay AM, et al. Amine oxidase inhibitors and development of neuroprotective drugs. Current Neuropharmacol 2004;2:153-68.
5. Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006;7: 295-309.
6. Young LT. Neuroprotective effects of antidepressant and mood stabilizing drugs. J Psychiatry Neurosci 2002;27:8-9.
7. Li XM, Xu H. Evidence for neuroprotective effects of antipsychotic drugs: implications for the pathophysiology and treatment of schizophrenia. Int Rev Neurobiol 2007;77:107-42.
8. Yu PH, Wright S, Fan EH, et al. Physiological and pathological implications of semicarbazide-sensitive amine oxidase. Biochim Biophys Acta 2003;1647:193-9.
9. Chen K, Maley J, Yu PH. Potential inplications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis. J Neurochem 2006;99:1413-24.
10. Nibuya M, Morinobu S, Duman RS Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and anti-depressant drug treatments. J Neurosci 1995;15:7539-47.
11. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996;16:2365-72.
12. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-9.
13. Frampton JE, Plosker GL, Masand PS. Selegiline transdermal system in the treatment of major depressive disorder. Drugs 2007;67: 257-65.
14. Riederer P, Lachenmayer L, Lause G. Clinical applications of MAO-mhibitors. Curr Med Chem 2004;11:2033-43.
15. Birks J, Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev 2003;(1):CD000442.
16. Popov N, Matthies H. Some effects of monoamine oxidase inhibitors on the metabolism of gamma-aminobutyric acid in rat brain. J Neurochem 1969;16:899-907.
17. Baker GB, Wong JT, Yeung JM, et al. Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA). J Affect Disord 1991;21:207-11.
18. Wood PL, Khan MA, Moskal JR, et al. Aldehyde load in ischemia-reperfusion brain injury: neuroprotection by neutralization of reactive aldehydes with phenelzine. Brain Res 2006;1122:184-90.
19. Ling L, Urichuk LJ, Sloley DB, et al. Synthesis of N-propargylphenelzine and analogues as neuroprotective agents. Bioorg Med Chem Lett 2001;11:2715-7.
20. Shuaib A, Kanthan R. Amplification of inhibitory mechanisms in cerebral ischemia: an alternative approach to neuronal protection. Histol Histopathol 1997;12:185-94.
21. Green AR, Hainsworth AH, Jackson DM. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology 2000;39:1483-94.
22. Michael-Titus AT, Bains S, Jeetle J, et al. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex - a possible mechanism of neuroprotection in major depression. Neuroscience 2000;100:681-4.
23. Seiler N. Oxidation of polyamines and brain injury. Neurochem Res 2000;25:471-90.
24. Wood PL, Khan MA, Kulow SR, et al. Neurotoxicity of reactive aldehydes: the concept of "aldehyde load" as demonstrated by neuroprotection with hydroxylamines. Brain Res 2006;1095:190-9.
25. Lovell MA, Xie C, Markesbery WR. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 2001;22:187-94.
26. Burke WJ, Li SW, Chung HD, et al. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 2004;25:101-15.
27. Springer JE, Azbill RD, Mark RJ, et al. 4-Hydroxynonenal, a lipid peroxidation product, rapidly accumulates following traumatic spinal cord injury and inhibits glutamate uptake. J Neurochem 1997;68:2469-76.
28. Marchitti SA, Deitrich RA, Vasiliou V. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev 2007;59:125-50.
29. Malorni W, Giammarioli AM, Matarnese P, et al. Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett 1998;426:155-9.
30. Maragos WF, Young KL, Altman CS, et al. Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgyline-treated rats and MAO-A deficient mice. Neurochem Res 2004;29:741-6.
31. Jiang J, Richardson JS, Yu PH. The contribution of cerebral vascular semicarbazide sensitive amine oxidase to cerebral amyloid angiopathy in Alzheimer's disease. Neuropathol Appl Neurobiol. In press.
32. Holt A, Berry MD, Boulton AA. On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. Neurotoxicology 2004;25:251-6.
33. Berry MD, Boulton AA. Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases. Neurotoxicol Teratol 2002;24:667-73.
34. Am OB, Amit T, Youdin MBH. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 2004;355:169-72.
35. Yu PH, Davis BA, Boulton AA. Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem 1992;35:3705-13.
36. Emilsson L, Saetre P, Balciuniene J, et al. Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer's disease patients. Neurosci Lett 2002;326:56-60.
37. Paslawski T, Knaus E, Iqbal N, et al. β-Phenylethylidenehydrazine, a novel inhibitor of GABA transaminase. Drug Dev Res 2001;54:35-9.